167 related articles for article (PubMed ID: 27610130)
1. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.
Kripp M; Merx K; Wirtz RM; Gaiser T; Eidt S; Schwaab J; Post S; Wenz F; Hochhaus A; Hofheinz RD; Erben P
Gastroenterol Res Pract; 2016; 2016():3481578. PubMed ID: 27610130
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
3. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
Liu S; Geng R; Lin E; Zhao P; Chen Y
Front Genet; 2021; 12():602160. PubMed ID: 33732282
[TBL] [Abstract][Full Text] [Related]
4. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
5. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
7. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
[TBL] [Abstract][Full Text] [Related]
8. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study.
Makatsoris T; Tsamandas AC; Strimpakos A; Alexopoulou Z; Dionysopoulos D; Pervana S; Konstantara A; Papakostas P; Samantas E; Rallis G; Dimou A; Pentheroudakis G; Papaparaskeva K; Psyrri A; Kalogeras KT; Syrigos K; Scopa CD; Fountzilas G
Anticancer Res; 2016 Apr; 36(4):1581-90. PubMed ID: 27069134
[TBL] [Abstract][Full Text] [Related]
9. [Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance].
Erben P; Wezel F; Wirtz R; Martini T; Stein D; Weis CA; Hartmann A; Bolenz C
Aktuelle Urol; 2017 Aug; 48(4):356-362. PubMed ID: 28750448
[No Abstract] [Full Text] [Related]
10. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract][Full Text] [Related]
12. Expression of the erbB/HER receptor family in the bovine uterus during the sexual cycle and the relation of this family to serum sex steroids.
Sağsöz H; Ketani MA; Saruhan BG
Biotech Histochem; 2012 Feb; 87(2):105-16. PubMed ID: 21299369
[TBL] [Abstract][Full Text] [Related]
13. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
[TBL] [Abstract][Full Text] [Related]
14. Mutations of EGFR in lung cancers and their implications for targeted therapy.
Shigematsu H; Gazdar AF
Discov Med; 2004 Dec; 4(24):444-7. PubMed ID: 20704946
[TBL] [Abstract][Full Text] [Related]
15. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer.
Moghbeli M; Makhdoumi Y; Soltani Delgosha M; Aarabi A; Dadkhah E; Memar B; Abdollahi A; Abbaszadegan MR
Biol Res; 2019 Jan; 52(1):2. PubMed ID: 30621788
[TBL] [Abstract][Full Text] [Related]
16. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G;
Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033
[TBL] [Abstract][Full Text] [Related]
18. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
19. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
